Argenica’s Stroke Trial Advances Unchanged

Argenica Therapeutics Ltd (AU:AGN) has released an update.

Argenica Therapeutics has received a green light from the independent Data Safety Monitoring Board (DSMB) to continue their Phase 2 clinical trial for ARG-007 without any protocol changes, following a safety review of the first 23 patients. The trial, which is 47% complete with 43 patients dosed, is on track to complete the dosing of all 92 patients by the second quarter of 2025. This positive progression is a significant step for Argenica, which aims to reduce brain tissue death after strokes and improve patient outcomes.

For further insights into AU:AGN stock, check out TipRanks’ Stock Analysis page.